Skip to main content

Table 3 Correlations of the change in GDF-15 with the change in other variables at 12 weeks

From: The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)

 

Empagliflozin, 10 mg/d

Placebo

Between-group difference

 

R

p value

R

p value

p value

Cardiac measurements

     

LVESV (mL)

 − 0.23

0.031

0.099

0.37

0.035

LVEDV (mL)

 − 0.29

0.0066

0.12

0.29

0.011

LVM (g/m2)

 − 0.10

0.32

0.03

0.77

0.36

LAVI (ml/m2)

 − 0.02

0.86

0.05

0.64

0.64

SBP (mmHg)

 − 0.20

0.052

 − 0.12

0.24

0.50

Metabolic measurements

     

Weight (kg)

 − 0.08

0.418

 − 0.24

0.020

0.13

HbA1c (mmol/L)

0.08

0.429

 − 0.15

0.147

0.096

BMI (kg/m2)

 − 0.10

0.394

 − 0.26

0.012

0.12

Renal measurements

     

Haematocrit (%)

 − 0.04

0.679

 − 0.03

0.76

0.94

Plasma volume (mL)

0.01

0.887

 − 0.07

0.498

0.55

eGFR (mL/min/1·73 m2)

 − 0.42

 < 0.0001

 − 0.53

 < 0.0001

0.68

  1. Pearson’s correlation between the change in GDF-15 and other variables. The increase in plasma GDF15 was inversely associated with the decrease in LVESV and LVEDV
  2. LVESV left ventricular end-systolic volume, LVEDV left ventricular end-diastolic volume, LVM left ventricular mas, LAVi left atrial volume index, SBP systolic blood pressure, HbA1c haemoglobin A1c, BMI body mass index, eGFR estimated glomerular filtration rate
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840